Fulltext

Four-year results following treatment of intrabony periodontal defects with an enamel matrix derivative alone or combined with a biphasic calcium phosphate

Pietruska, Malgorzata ; Pietruski, Jan ; Nagy, Katalin ; Brecx, Michel ; Arweiler, Nicole ; Sculean, Anton

In: Clinical Oral Investigations, 2012, vol. 16, no. 4, p. 1191-1197

Ajouter à la liste personnelle
    Titre
    • Four-year results following treatment of intrabony periodontal defects with an enamel matrix derivative alone or combined with a biphasic calcium phosphate
    Auteur
    • Pietruska, Malgorzata. Department of Periodontal and Oral Mucosa Diseases, Medical Academy Bialystok, Bialystok, Poland
    • Pietruski, Jan. Dental Practice, Bialystok, Poland
    • Nagy, Katalin. Department of Oral Surgery, Szentgyörgyi Albert University, Szeged, Hungary
    • Brecx, Michel. Department of Periodontology, Catholic University of Louvain, Brussels, Belgium
    • Arweiler, Nicole. Department of Periodontology, University of Marburg, Marburg, Germany
    • Sculean, Anton. Department of Periodontology, Dental School University of Bern, Freiburgstrasse 7, 3010, Bern, Switzerland
    Type de document
    • Postprint
    Langue
    • Anglais
    Publié dans
    • Clinical Oral Investigations, 2012, vol. 16, no. 4, p. 1191-1197. Springer-Verlag
    Autre version électronique
    Identifiant OAI-PMH
    • oai:doc.rero.ch:316760
    Summary
    The aim of this study was to evaluate the 4-year clinical outcomes following regenerative surgery in intrabony defects with either EMD + BCP or EMD. Twenty-four patients with advanced chronic periodontitis, displaying one-, two-, or three-walled intrabony defect with a probing depth of at least 6mm, were randomly treated with either EMD + BCP (test) or EMD alone (control). The following clinical parameters were evaluated at baseline, at 1year and at 4years after regenerative surgery: plaque index, gingival index, bleeding on probing, probing depth, gingival recession, and clinical attachment level (CAL). The primary outcome variable was CAL. No differences in any of the investigated parameters were observed at baseline between the two groups. The test group demonstrated a mean CAL change from from 10.8 ± 1.6mm to 7.4 ± 1.6mm (p < 0.001) and to 7.6 ± 1.7mm (p < 0.001) at 1 and 4years, respectively. In the control group, mean CAL changed from 10.4 ± 1.3 at baseline to 6.9 ± 1.0mm (p < 0.001) at 1year and 7.2 ± 1.2mm (p < 0.001) at 4years. At 4years, two defects in the test group and three defects in the control group have lost 1mm of the CAL gained at 1year. Compared to baseline, at 4years, a CAL gain of ≥3mm was measured in 67% of the defects (i.e., in 8 out of 12) in the test group and in 75% of the defects (i.e., in 9 out of 12) in the control group. There were no statistically significant differences in any of the investigated parameters at 1 and at 4years between the two groups. Within their limits, the present results indicate that: (a) the clinical improvements obtained with both treatments can be maintained over a period of 4years, and (b) in two- and three-walled intrabony defects, the addition of BCP did not additionally improve the outcomes obtained with EMD alone. In two- and three-walled intrabony defects, the combination of EMD + BCP did not show any advantage over the use of EMD alone